1. Introduction
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Function
4.4. Function Value Chain Analysis
5. Global Influenza Vaccine Market, By Vaccine Technology
5.1. Introduction
5.2. Trivalent
5.3. Quadrivalent
6. Global Influenza Vaccine Market, By End-User
6.1. Introduction
6.2. Children
6.3. Adolescents
6.4. Adults
6.5. Elderly
7. Global Influenza Vaccine Market, By Geography
7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. UK
7.4.2. Germany
7.4.3. Italy
7.4.4. Spain
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Israel
7.5.2. Saudi Arabia
7.5.3. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. Japan
7.6.3. India
7.6.4. Australia
7.6.5. South Korea
7.6.6. Taiwan
7.6.7. Thailand
7.6.8. Indonesia
7.6.9. Others
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles.
9.1. Seqirus
9.2. GlaxoSmithKline plc.
9.3. Sanofi Pasteur SA.
9.4. Novavax, Inc.
9.5. Emergent BioSolutions Inc.
9.6. CSL Limited
9.7. Pfizer Limited
9.8. Gamma Vaccines Pty Ltd
9.9. BioDiem
9.10. F. Hoffmann-La Roche Ltd